Literature DB >> 26836231

Investigating the Radioresistant Properties of Lung Cancer Stem Cells in the Context of the Tumor Microenvironment.

Ryan Chan1, Pallavi Sethi1, Amar Jyoti1, Ronald McGarry1, Meenakshi Upreti1.   

Abstract

Lung cancer is the most common cause of cancer-related deaths worldwide and non-small cell lung cancer (NSCLC) accounts for ~85% of all lung cancer. While recent research has shown that cancer stem cells (CSC) exhibit radioresistant and chemoresistant properties, current cancer therapy targets the bulk of the tumor burden without accounting for the CSC and the contribution of the tumor microenvironment. CSC interaction with the stroma enhances NSCLC survival, thus limiting the efficacy of treatment. The aim of this study was to elucidate the role of CSC and the microenvironment in conferring radio- or chemoresistance in an in vitro tumor model for NSCLC. The novel in vitro three-dimensional (3D) NSCLC model of color-coded tumor tissue analogs (TTA) that we have developed is comprised of human lung adenocarcinoma cells, fibroblasts, endothelial cells and NSCLC cancer stem cells maintained in low oxygen conditions (5% O2) to recapitulate the physiologic conditions in tumors. Using this model, we demonstrate that a single 5 Gy radiation dose does not inhibit growth of TTA containing CSC and results in elevated expression of cytokines (TGF-α, RANTES, ENA-78) and factors (vimentin, MMP and TIMP), indicative of an invasive and aggressive phenotype. However, combined treatment of single dose or fractionated doses with cisplatin was found to either attenuate or decrease the proliferative effect that radiation exposure alone had on TTA containing CSC maintained in hypoxic conditions. In summary, we utilized a 3D NSCLC model, which had characteristics of the tumor microenvironment and tumor cell heterogeneity, to elucidate the multifactorial nature of radioresistance in tumors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26836231      PMCID: PMC4762254          DOI: 10.1667/RR14285.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  53 in total

1.  Simultaneous maintenance of human cord blood SCID-repopulating cells and expansion of committed progenitors at low O2 concentration (3%).

Authors:  Zoran Ivanovic; Francis Hermitte; Philippe Brunet de la Grange; Bernard Dazey; Francis Belloc; Francis Lacombe; Gérard Vezon; Vincent Praloran
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

2.  Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation.

Authors:  R K Schmidt-Ullrich; R B Mikkelsen; P Dent; D G Todd; K Valerie; B D Kavanagh; J N Contessa; W K Rorrer; P B Chen
Journal:  Oncogene       Date:  1997-09-04       Impact factor: 9.867

Review 3.  Formation of cytoskeletal elements during mouse embryogenesis. III. Primary mesenchymal cells and the first appearance of vimentin filaments.

Authors:  W W Franke; C Grund; C Kuhn; B W Jackson; K Illmensee
Journal:  Differentiation       Date:  1982       Impact factor: 3.880

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  Tumor-Endothelial Cell Three-dimensional Spheroids: New Aspects to Enhance Radiation and Drug Therapeutics.

Authors:  Meenakshi Upreti; Azemat Jamshidi-Parsian; Nathan A Koonce; Jessica S Webber; Sunil K Sharma; Alexzander Aa Asea; Mathew J Mader; Robert J Griffin
Journal:  Transl Oncol       Date:  2011-12-01       Impact factor: 4.243

6.  Tumor microenvironment complexity: emerging roles in cancer therapy.

Authors:  Melody A Swartz; Noriho Iida; Edward W Roberts; Sabina Sangaletti; Melissa H Wong; Fiona E Yull; Lisa M Coussens; Yves A DeClerck
Journal:  Cancer Res       Date:  2012-03-13       Impact factor: 12.701

7.  Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition).

Authors:  Lary A Robinson; John C Ruckdeschel; Henry Wagner; Craig W Stevens
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

Review 8.  Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions.

Authors:  D T Denhardt; B Feng; D R Edwards; E T Cocuzzi; U M Malyankar
Journal:  Pharmacol Ther       Date:  1993-09       Impact factor: 12.310

9.  Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas.

Authors:  Maryline Dauphin; Coralie Barbe; Sarah Lemaire; Béatrice Nawrocki-Raby; Eymeric Lagonotte; Gonzague Delepine; Philippe Birembaut; Christine Gilles; Myriam Polette
Journal:  Lung Cancer       Date:  2013-04-04       Impact factor: 5.705

10.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

Authors:  Giulia Bertolini; Luca Roz; Paola Perego; Monica Tortoreto; Enrico Fontanella; Laura Gatti; Graziella Pratesi; Alessandra Fabbri; Francesca Andriani; Stella Tinelli; Elena Roz; Roberto Caserini; Salvatore Lo Vullo; Tiziana Camerini; Luigi Mariani; Domenico Delia; Elisa Calabrò; Ugo Pastorino; Gabriella Sozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-10       Impact factor: 11.205

View more
  11 in total

Review 1.  The application of three-dimensional cell culture in clinical medicine.

Authors:  Qiao Chen; Youbin Wang
Journal:  Biotechnol Lett       Date:  2020-09-15       Impact factor: 2.461

2.  Epithelial-mesenchymal crosstalk induces radioresistance in HNSCC cells.

Authors:  Teresa Bernadette Steinbichler; Abdelmoez Alshaimaa; Metzler Veronika Maria; Dejaco Daniel; Riechelmann Herbert; Dudas Jozsef; Skvortsova Ira-Ida
Journal:  Oncotarget       Date:  2017-12-14

Review 3.  The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer.

Authors:  Dimakatso Alice Senthebane; Arielle Rowe; Nicholas Ekow Thomford; Hendrina Shipanga; Daniella Munro; Mohammad A M Al Mazeedi; Hashim A M Almazyadi; Karlien Kallmeyer; Collet Dandara; Michael S Pepper; M Iqbal Parker; Kevin Dzobo
Journal:  Int J Mol Sci       Date:  2017-07-21       Impact factor: 5.923

Review 4.  Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy.

Authors:  Sameera S Kumar; Kristin A Higgins; Ronald C McGarry
Journal:  Front Oncol       Date:  2017-09-04       Impact factor: 6.244

5.  The effect of foxp3-overexpressing Treg cells on non-small cell lung cancer cells.

Authors:  Jiangzhou Peng; Zigang Yu; Lei Xue; Jiabin Wang; Jun Li; Degang Liu; Qiang Yang; Yihui Lin
Journal:  Mol Med Rep       Date:  2018-02-13       Impact factor: 2.952

Review 6.  Overview of Cancer Stem Cells and Stemness for Community Oncologists.

Authors:  Justin D Lathia; Huiping Liu
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

Review 7.  Role of metabolism in cancer cell radioresistance and radiosensitization methods.

Authors:  Le Tang; Fang Wei; Yingfen Wu; Yi He; Lei Shi; Fang Xiong; Zhaojian Gong; Can Guo; Xiayu Li; Hao Deng; Ke Cao; Ming Zhou; Bo Xiang; Xiaoling Li; Yong Li; Guiyuan Li; Wei Xiong; Zhaoyang Zeng
Journal:  J Exp Clin Cancer Res       Date:  2018-04-23

Review 8.  Clinical Application Perspectives of Lung Cancers 3D Tumor Microenvironment Models for In Vitro Cultures.

Authors:  Irena Wieleba; Kamila Wojas-Krawczyk; Paweł Krawczyk; Janusz Milanowski
Journal:  Int J Mol Sci       Date:  2022-02-18       Impact factor: 5.923

Review 9.  An emerging role of radiation‑induced exosomes in hepatocellular carcinoma progression and radioresistance (Review).

Authors:  Qing Fan; Yue Yu; Yueling Zhou; Sheng Zhang; Chunli Wu
Journal:  Int J Oncol       Date:  2022-03-10       Impact factor: 5.650

10.  Tumor radioresistance caused by radiation-induced changes of stem-like cell content and sub-lethal damage repair capability.

Authors:  Roman Fukui; Ryo Saga; Yusuke Matsuya; Kazuo Tomita; Yoshikazu Kuwahara; Kentaro Ohuchi; Tomoaki Sato; Kazuhiko Okumura; Hiroyuki Date; Manabu Fukumoto; Yoichiro Hosokawa
Journal:  Sci Rep       Date:  2022-01-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.